Telehealth buprenorphine care for people with opioid use disorder in vulnerable settings
Right Tools, Right Time, Right Place: Telehealth for Opioid Use Disorder in Vulnerable Settings
This project will see if Boulder Care's telehealth platform can deliver buprenorphine treatment effectively to people with opioid use disorder in vulnerable communities.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 250 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Boulder Care Industry-sponsored |
| Locations | 1 site (Portland, Oregon) |
| Trial ID | NCT07169409 on ClinicalTrials.gov |
What this trial studies
This Phase 1 interventional study tests a telemedicine-delivered buprenorphine program offered by Boulder Care in partnership with NIDA, focusing on vulnerable and culturally specific populations. Participants are English-speaking adults with a history of opioid use disorder who are starting buprenorphine or are within 45 days of starting or restarting it. The protocol delivers medication and care through Boulder Care's telehealth platform at a Portland, Oregon site and monitors feasibility, reach, equity, and early clinical outcomes. Key exclusions include buprenorphine allergy, plans to leave a Boulder Care-affiliated state within 12 months, and untreated health conditions that would preclude participation.
Who should consider this trial
Good fit: Ideal candidates are English-speaking adults with opioid use disorder who are starting or restarted buprenorphine within the past 45 days and can receive care through Boulder Care in Portland.
Not a fit: People allergic to buprenorphine, those planning to move out of a Boulder Care-affiliated state within a year, or those with untreated medical or mental conditions preventing participation are unlikely to benefit.
Why it matters
Potential benefit: If successful, it could expand convenient, culturally sensitive access to buprenorphine care for underserved people with opioid use disorder and improve treatment retention.
How similar studies have performed: Previous studies have shown telehealth-delivered buprenorphine can improve access and retention, but this platform- and equity-focused implementation approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * History of Opioid Use Disorder (OUD) * Starting OUD treatment with buprenorphine, or within 45 days of starting or restarting this medication * Speak and understand English Exclusion Criteria: * History of allergic reaction to buprenorphine * Plans to move out of a Boulder Care-affiliated state site in the next 12 months (precluding continuation of care) * Untreated mental or medical health conditions that, in the opinion of the participant, would preclude study participation
Where this trial is running
Portland, Oregon
- Boulder Care — Portland, Oregon, United States (Recruiting)
Study contacts
- Study coordinator: Andrea Baron, MPH
- Email: andrea.baron@boulder.care
- Phone: 408-483-2766
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.